.

Kuliah Farmakologi Blok 8TA 201,3/2014 LLltt/20L3

d. Stabilisasi membran..... d. Stabilisasi membran..,,.

1. Citicholine 2. Piracetam
Penggunaan klinis: . Derivat neurotansmiter GABA
American Stroke Association. 2007 . Mekanisme kerja:
Citir*linc, ao agent *m app€ars ls stabiiize r**mtranr:s.
has treetr rffiled in mveral cliaig:al slrdigs.:+a Th€ iri*l$ Sid
flst dernr'rlqlra{e *fl'ilb*}. i}flln treelffsilt A suhE*l1l,rsl$ sleta*
analyris rcp*rled that Fa:ieirts xilh m*rierits tr, st-*er* $mhe
mighttle h.lprri if lhe medi;ilioB *..ss sraued s,!*rhr 3,4 h$firs
of snirt $l syfl$toms.ss This tinding shouid a$l l,ff r*oriid-
*red defi.nitive but rethnr r mti+nillc l-or'fitrlher te$tirg *frh*
rnedicati** in this :ubgrroup ot'pstieilli" Srteral trials nf t
'!! uity.of M6#tclBs. univelqlty aeni*,1

d. Stabilisasi membran..... d. Stabilisasi membran.....

2. Piracetam 2. Piracetam
Farmakokinetik: Kontraindikasi:
. Absorpsicepat per oral . Penurunan fs ginlal I kurangi dosis
. Kadarpuncakplasma:30menit . Gagalginjal terminal

' Bioavailibilitas:-'100%
. Skokehemoragik
. Menembussawardarah-otakdan plasenta
. Wanita hamil dan menyusur

. Ekresi melalui urin (dalam bentuk utuh) Dosis Terapi: tergantung indikasi
. Gg kognitif, venigo) 2,4- 4,Bglhari
. Disleksia) 3,2glhari
ES: fiarang, <2%)
. Mioklonus kortlkal) 7 ,2 -24,0 glhari
Hiperkinesia, pe1 BB, nayousness, somnolen, depresi, astenia
. Anemia sel sabit ) profilaksis. 160 mg/kg/hari; terapi. 300 mglkg/hari

d. Stabilisasi membran.....
e. Penghambat Kanal lon

2. Piracetam 1. Fosphenytoin
Penggunaan klinis:
. Na*-channel antagonist
.
. Stoke: American Stoke Association, 2007
BuKi klinis: no improvement of functional outcome at 3 months

tlitrfit iJu$ tre{finsm.lr{ PlteEtm a,sF brs bem t6tr*, ht

2. Nimodipine

.'
*r'anl rlirdrsl tids. ry10: laixad r*qlts,Br 5,a f{miews Bf Ca2*-channelantagonist
&e medistim alxr iare recdxd differi*g {*trfusi9m: Buktiklinis;
rhhilrEh *E rEDfi mn], he efftrriyr ia smf, lBrient* uirh
ishemic rtrcke. lh(re ffiI br I rend for in*rard risk of
. no improvement of neuronal and functional outcome
declb Hrr)ffg tfititrntr $iel*d Tith Firwlmjnr;dAt pat*nl , no difference in mortalityor neurologic outcome
llu datlr ua Epl sutfi{:i rll! c}Hr ilu ilrar fr fltrrlturu .;*rur
thc xtilitj of th!! mJ&c:s()n.
3. Flunarizine
. Gangguan Kognttil, vertgo, mtoKonus Kmrat, disleksia, . Ca2*-channelantagonist
anemia sel sabit . Buktiklinis: no improvement of neuronal & functional outcome

,,'".rl r$*iry.r:. . ... Fqcttfysttrle$&iirftJtri-v*r$itiolRii*r: : ..I 4e